The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in the treatment of inflammatory diseases. Boehringer Ingelheim. 2002 Branger J, et al
ImClone Systems and Bristol-Myers Squibb said yesterday that they would begin to provide their cancer drug, Erbitux, to a limited number of colorectal cancer patients who have exhausted other treatment options.